Skip to content

Use of Shwasahara Dashemani Yog in the Tamaka shwasa Effect of shwasahara dashemani on tamaka shwasha

A Comparative study of Shwasahara Dashemani in the Management of Tamaka Shwasa(Bronchial Asthma)in Children-A randomized open label clinical Trail - EOSDOTS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/04/008282
Enrollment
50
Registered
2017-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having sign and symptoms of bronchial asthma

Interventions

Intervention1: in Group A Shwasahara Dashemani Avaleha referance carak samhita sutra sthan slok no 4/37: 10 content in Shwasahara Dashemani Avaleha namely Shati Hedychium spicatum Pushkara mool Inula

Sponsors

Director IPGT and RA GAU JAMNAGAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of 2 â?? 12 years of age of either sex. Diagnosed cases of Tamaka Shwasa with at least 2 episodes of asthma symptoms during the previous year. Mild persistent asthmatic patients. Patients on other drug therapy will be included only after completion of wash out period of three weeks.

Exclusion criteria

Exclusion criteria: Children of age below 2 years and above 12 years. Patients with status asthmatics. Evidence of active Concomitant Pulmonary Diseases other than asthma. Evidence of requirement of intubations for asthma, or had been hospitalized for asthma within one month before, Unresolved Sinus Disease or an unresolved upper or lower respiratory tract infection within 2 weeks. Concomitant severe systemic disease (cardiovascular, renal, hepatic, endocrine, haematological, neurologicaletc.)

Design outcomes

Primary

MeasureTime frame
relieve in the sign and symptom of shwasa roga or Bronchial asthmaTimepoint: Drug trail time 6 weeks Follow up time 8 weeks

Secondary

MeasureTime frame
To prevent the recurrence of attack of breathlessness To increase the immunity against allergensTimepoint: 6 weeks

Countries

India

Contacts

Public ContactDr V K Kori

IPGT AND RA JAMNAGAR

drkspatel2007@yahoo.co.in9427574566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026